Apixaban in Patients With Left Ventricular Thrombus

Left Ventricular Thrombus Clinical Trial

Official title:
Apixaban in Patients With Left Ventricular Thrombus Post Myocardial Infarction; A Randomized Clinical Trial

Status Completed

Clinical Trial Summary

Open label randomized controlled clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in treating left ventricular thrombus in patients with acute or recent myocardial infarction (MI).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05208398
Study type	Interventional
Source	Saud Al Babtain Cardiac Center
Contact
Status	Completed
Phase	Phase 3
Start date	February 18, 2018
Completion date	September 30, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05077683` - Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIF	Phase 3
Recruiting	`NCT04970576` - Rivaroxaban in Left Ventricular Thrombus	Phase 4
Not yet recruiting	`NCT03415386` - Optimized Antithrombotic Therapy of Acute Myocardial Infarction With Left Ventricular Mural Thrombus	Phase 4
Completed	`NCT04871126` - Predictive Value of Inflammatory Indexes and CHA2DS2-VASc Score for LVT in ANT-MI With Left Ventricular Dysfunction
Recruiting	`NCT03764241` - Treatment of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant	Phase 3
Recruiting	`NCT04829825` - The "MyoThrombus" Study
Not yet recruiting	`NCT03786757` - Prevention of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant (EARLYmyo-LVT Ⅱ)	Phase 3